Science and Research

Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia

BACKGROUND: Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide. Despite effective antimicrobial therapy, CAP can induce pulmonary endothelial hyperpermeability resulting in life-threatening lung failure due to an exaggerated host-pathogen interaction. Treatment of acute lung injury is mainly supportive because key elements of inflammation-induced barrier disruption remain undetermined. Angiopoietin-1 (Ang-1)-mediated Tie2 activation reduces, and the Ang-1 antagonist Ang-2 increases, inflammation and endothelial permeability in sepsis. Vasculotide (VT) is a polyethylene glycol-clustered Tie2-binding peptide that mimics the actions of Ang-1. The aim of our study was to experimentally test whether VT is capable of diminishing pneumonia-induced lung injury. METHODS: VT binding and phosphorylation of Tie2 were analyzed using tryptophan fluorescence spectroscopy and phospho-Tie-2 enzyme-linked immunosorbent assay. Human and murine lung endothelial cells were investigated by immunofluorescence staining and electric cell-substrate impedance sensing. Pulmonary hyperpermeability was quantified in VT-pretreated, isolated, perfused, and ventilated mouse lungs stimulated with the pneumococcal exotoxin pneumolysin (PLY). Furthermore, Streptococcus pneumoniae-infected mice were therapeutically treated with VT. RESULTS: VT showed dose-dependent binding and phosphorylation of Tie2. Pretreatment with VT protected lung endothelial cell monolayers from PLY-induced disruption. In isolated mouse lungs, VT decreased PLY-induced pulmonary permeability. Likewise, therapeutic treatment with VT of S. pneumoniae-infected mice significantly reduced pneumonia-induced hyperpermeability. However, effects by VT on the pulmonary or systemic inflammatory response were not observed. CONCLUSIONS: VT promoted pulmonary endothelial stability and reduced lung permeability in different models of pneumococcal pneumonia. Thus, VT may provide a novel therapeutic perspective for reduction of permeability in pneumococcal pneumonia-induced lung injury.

  • Gutbier, B.
  • Jiang, X.
  • Dietert, K.
  • Ehrler, C.
  • Lienau, J.
  • Van Slyke, P.
  • Kim, H.
  • Hoang, V. C.
  • Maynes, J. T.
  • Dumont, D. J.
  • Gruber, A. D.
  • Weissmann, N.
  • Mitchell, T. J.
  • Suttorp, N.
  • Witzenrath, M.

Keywords

  • Acute lung injury
  • Angiopoietins
  • Pneumococcal pneumonia
  • Pneumolysin
  • Vasculotide
Publication details
DOI: 10.1186/s13054-017-1851-6
Journal: Critical care (London, England)
Pages: 274 
Number: 1
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: JLU
Access-Number: 29132435
See publication on PubMed

DZL Engagements

chevron-down